SERVICES OVERVIEW
Poor translatability of traditional in vitro models is a major reason why only 8% of the drugs that show preclinical efficacy progress after Phase I clinical trials. It’s time to rethink convention.
HUB Organoids provide an accurate representation of patient pathobiology, allowing higher-quality drug candidates to advance to clinical trials. HUB Organoids can support decision-making at every step of the drug development pipeline and help you bring life-changing treatments to patients.
Leverage the predictive power of HUB Organoids to select the most promising clinical candidates with confidence
Accurately stratify and customize patient treatment with our co-clinical testing platform
Innovate novel disease models and assays and bring your research to the next level
CONTENT HIGHLIGHT
Read our Proof-of-concept study that demonstrates how HUB Organoids can streamline the entire preclinical drug development process, resulting in significant savings in time, cost, and resources.
